DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

A-Hydrocort (Hydrocortisone Sodium Succinate) - Summary



A-Hydrocort sterile powder contains hydrocortisone sodium succinate as the active ingredient. Hydrocortisone sodium succinate, is a white, or nearly white, odorless, hygroscopic, amorphous solid. It is very soluble in water and in alcohol, very slightly soluble in acetone and insoluble in chloroform.

When oral therapy is not feasible, and the strength, dosage form and route of administration of the drug reasonably lend the preparation to the treatment of the condition, A-Hydrocort sterile powder is indicated for intravenous or intramuscular use in the following conditions:

1. Endocrine Disorders

  • Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance)

  • Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used)

  • Preoperatively and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful

  • Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected

  • Congenital adrenal hyperplasia

  • Hypercalcemia associated with cancer

  • Nonsuppurative thyroiditis

2. Rheumatic Disorders

As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:

  • Post-traumatic osteoarthritis

  • Synovitis of osteoarthritis

  • Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)

  • Acute and subacute bursitis

  • Epicondylitis

  • Acute nonspecific tenosynovitis

  • Acute gouty arthritis

  • Psoriatic arthritis

  • Ankylosing spondylitis

3. Collagen Diseases

During an exacerbation or as maintenance therapy in selected cases of:

  • Systemic lupus erythematosus

  • Systemic dermatomyositis (polymyositis)

  • Acute rheumatic carditis

4. Dermatologic Diseases

  • Pemphigus

  • Severe erythema multiforme (Stevens-Johnson syndrome)

  • Exfoliative dermatitis

  • Bullous dermatitis herpetiformis

  • Severe seborrheic dermatitis

  • Severe psoriasis

  • Mycosis fungoides

5. Allergic States

Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in:

  • Bronchial asthma

  • Contact dermatitis

  • Atopic dermatitis

  • Serum sickness

  • Seasonal or perennial allergic rhinitis

  • Drug hypersensitivity reactions

  • Urticarial transfusion reactions

  • Acute noninfectious laryngeal edema (epinephrine is the drug of first choice)

6. Ophthalmic Diseases

Severe acute and chronic allergic and inflammatory processes involving the eye, such as:

  • Herpes zoster ophthalmicus

  • Iritis, iridocyclitis

  • Chorioretinitis

  • Diffuse posterior uveitis and choroiditis

  • Optic neuritis

  • Sympathetic ophthalmia

  • Anterior segment inflammation

  • Allergic conjunctivitis

  • Allergic corneal marginal ulcers

  • Keratitis

7. Gastrointestinal Diseases

To tide the patient over a critical period of the disease in:

  • Ulcerative colitis (systemic therapy)

  • Regional enteritis (systemic therapy)

8. Respiratory Diseases

  • Symptomatic sarcoidosis

  • Berylliosis

  • Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy

  • LoefflerÂ’s syndrome not manageable by other means

  • Aspiration pneumonitis

9. Hematologic Disorders

  • Acquired (autoimmune) hemolytic anemia

  • Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated)

  • Secondary thrombocytopenia in adults

  • Erythroblastopenia (RBC anemia)

  • Congenital (erythroid) hypoplastic anemia

10. Neoplastic Diseases

For palliative management of:

  • Leukemias and lymphomas in adults

  • Acute leukemia of childhood

11. Edematous States

To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus

12. Nervous System

Acute exacerbations of multiple sclerosis

13. Miscellaneous

  • Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy

  • Trichinosis with neurologic or myocardial involvement

See all A-Hydrocort indications & dosage >>


Published Studies Related to A-Hydrocort (Hydrocortisone)

Interactions between bupropion and 3,4-methylenedioxymethamphetamine in healthy subjects. [2015]
3,4-Methylenedioxymethamphetamine (MDMA; "ecstasy") is a popular recreational drug. The aim of the present study was to explore the role of dopamine in the psychotropic effects of MDMA using bupropion to inhibit the dopamine and norepinephrine transporters through which MDMA releases dopamine and norepinephrine by investigating.

Continuous Subcutaneous Hydrocortisone Infusion Therapy in Addison's Disease: A Randomized, Placebo-Controlled Clinical Trial. [2014]
CONCLUSIONS: Biochemical measurements indicate similar cortisol exposure during

Clobetasol propionate, 0.05%, vs hydrocortisone, 1%, for alopecia areata in children: a randomized clinical trial. [2014]
IMPORTANCE: Alopecia areata is an idiopathic cause of hair loss with limited therapeutic repertoire. OBJECTIVE: To compare the efficacy and safety of a high- vs low-potency topical corticosteroid in pediatric patients...

Randomised controlled trial of the effects of L-ornithine on stress markers and sleep quality in healthy workers. [2014]
CONCLUSION: L-ornithine supplementation has the potential to relieve stress and

Effects of Jitai tablet, a traditional Chinese medicine, on plasma adrenocorticotropic hormone and cortisol levels in heroin addicts during abstinence. [2014]
cortisol in heroin addicts given Jitai tablet treatment during abstinence... CONCLUSIONS: Heroin addicts could respond to Jitai tablets through changes in the

more studies >>

Clinical Trials Related to A-Hydrocort (Hydrocortisone)

The Influence of Different Hydrocortisone Replacement Doses on the Partitioning and Flexibility of Ectopic Lipids in Patients With Corticotropic Hypopituitarism [Recruiting]
This study aims at assessing the effect of today's standard of hydrocortisone dosage versus previous hydrocortisone dosage on flexibility and partitioning of ectopic lipid depots (IMCL and IHCL) after a standardised fat load followed by a short-term aerobic exercise in patients with corticotropic pituitary insufficiency.

Ultradian Subcutaneous Hydrocortisone Infusion in Addison Disease and Congenital Adrenal Hyperplasia [Recruiting]

Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia [Completed]
This study will test a new, extended release form of hydrocortisone called Chronocort in patients with congenital adrenal hyperplasia (CAH). People with CAH do not make enough of the adrenal hormones cortisol and aldosterone, and their adrenal glands make too much of the sex hormone androgen. Medicines called glucocorticoids (hydrocortisone, dexamethasone and prednisone) are currently used to treat CAH, but finding the best dose of these drugs that effectively lowers androgens without causing undesirable side effects, such as weight gain and slow growth rate in children, is often difficult to achieve. Adolescents and adults with CAH due to 21-hydroxylase deficiency may be eligible for this study. Children 16 years of age and older are eligible with confirmation by bone age that they are no longer growing. Participants undergo the following tests and procedures during two inpatient visits one month apart at the NIH Clinical Center:

- Medical history and physical examination.

- Medications: Following 7 days of Cortef (standard drug treatment for CAH), patients

begin taking Chronocort on day 3 of hospitalization and continue the tablets once a day for 1 month.

- Blood tests: A catheter (plastic tube) is inserted in a vein and left in place for

frequent blood draws in order to avoid repeated needlesticks. Blood is drawn for chemistries, blood count, pregnancy test in women, and for serial tests (up to 26 samples in a 24-hour period) to measure hormone levels.

- 24-hour urine test.

- Height and weight measurements.

Between the two hospitalizations, patients are contacted by NIH weekly to check for possible side effects from Chronocort. Two weeks after the first visit, patients also will have blood drawn by their regular doctor or a local clinic. A few days before the second hospitalization, patients undergo a 20-minute telephone questionnaire about energy level and well being. About 30 days after discharge from the second hospitalization, patients are followed up with a telephone call to see how they are doing.

Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insufficiency [Completed]
This is a randomised, controlled, open, two-armed, two-period cross-over, multi-centre phase II/III study to assess the safety, tolerability and pharmacokinetics of once-daily oral modified-release hydrocortisone in comparison to conventional thrice-daily oral hydrocortisone tablets in patients with adrenal insufficiency

Sensitivity of Short and Long Allele Carriers of the 5-HTTLPR to Environmental Threat Post Hydrocortisone Administration [Completed]
The current study will test the causal relationship between elevated levels of cortisol and the serotonin transporter gene (5-HTTLPR) as these factors influence sensitivity to environmental threat. The investigators predict that carriers of the short allele of the serotonin transporter gene who have elevated cortisol levels will be most sensitive to threatening environments, whereas carriers of the long allele who do not have elevated cortisol (placebo subjects) will be least sensitive.

more trials >>

Page last updated: 2015-08-10

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015